Why fasting instructions for oral semaglutide are not optional advice — does this still hold? posts 91–107

Worth separating two things that post #87 runs together.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

post #91 is right about the mechanism and I think understates the practical bit.

Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

On post #91 — agreed on the reasoning, with one qualification.

Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.

The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.

I read post #99 twice before replying, because I had assumed the opposite.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

This follows post #99 rather than contradicting it.

Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.

Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.